Citi analyst Yigal Nochomovitz maintains $Apellis Pharmaceuticals (APLS.US)$ with a buy rating, and maintains the target price at $63.
According to TipRanks data, the analyst has a success rate of 45.5% and a total average return of 12.5% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Apellis Pharmaceuticals (APLS.US)$'s main analysts recently are as follows:
Complement inhibitors Syfovre and Izervay have been approved for geographic atrophy, focusing on decelerating the expansion of atrophy in the retina rather than a functional benefit such as vision improvement, the endpoint for anti-VEGFs in wAMD. Key opinion leader consultants are generally hesitant to recommend Syfovre or Izervay to patients, with projections that at their peak, only 20%-25% of patients will be suitable candidates.
A recent survey of U.S. retinal specialists indicates a continued overall growth for the complement inhibitor class with an increase in prescribing for both Syfovre and its competitor product. The survey suggests that Syfovre maintains its position as the market leader and has an advantage when it comes to initiating treatment in new patients.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
